Age-related macular degeneration is a leading cause of visual impairment in older adults. In its exudative form, repeated intravitreal injections of anti-VEGF agents are required to control disease activity. A new formulation of aflibercept at a higher dose (8 mg) has been developed with the aim of extending the interval between injections.
This multicenter retrospective real-world observational study will evaluate the effect of switching to aflibercept 8 mg in patients with refractory or dependent exudative age-related macular degeneration. Clinical data collected during routine care will be analyzed to compare injection intervals, treatment burden, visual outcomes, anatomical outcomes, and safety before and after the switch.
Adults (≥18 years) with exudative (neovascular) age-related macular degeneration
Treated with intravitreal anti-VEGF therapy for more than 1 year
Switched to aflibercept 8 mg before July 31, 2025
Injection interval strictly less than 12 weeks prior to switch
High myopia (axial length > 26 mm or spherical equivalent < -6 diopters)
Angioid streaks
Moderate or severe diabetic retinopathy
History of diabetic macular edema